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  73 
Abstract (word count = 250) 74 
Objective: To determine the efficacy and tolerability of quetiapine as compared to placebo or 75 
other interventions for psychosis in parkinsonism. 76 
Design: Systematic review 77 
Participants: Subjects with a diagnosis of parkinsonism participating in randomized controlled 78 
trials (RCTS) investigating the efficacy and tolerability of quetiapine on psychotic symptoms 79 
within a defined follow-up period. 80 
Measurements: PubMed, Cochrane Register of Controlled Trials, and EMBASE were searched 81 
for articles published from January 1991 to October 2017. The process adhered to the Preferred 82 
Reporting Items of Systematic Reviews and Meta-Analyses format. Study methodology, patient- 83 
and treatment-level data were independently extracted and summarized using descriptive 84 
statistics. Studies underwent quality assessment for risk of bias.  85 
Results: 17,615 unique records were identified and seven RCTs (total of 241 subjects) met 86 
inclusion criteria. Five RCTs were placebo-controlled and two compared quetiapine against 87 
clozapine. Mean study duration was 12 weeks and mean daily quetiapine dose was 103 mg per 88 
day (range of 12.5 mg to 300 mg). In four of five placebo-controlled RCTs, quetiapine failed to 89 
demonstrate significant improvement of PP compared to placebo. In two clozapine-comparator 90 
RCTs, quetiapine was better tolerated but no more effective than clozapine. Across all RCTs, 91 
mean completion rates for quetiapine, clozapine, and placebo were 66%, 68.5%, and 66%, 92 
respectively. Quetiapine did not significantly worsen motor function.       93 
Conclusion: The efficacy and completion rate of quetiapine in RCTs for psychosis in 94 
parkinsonism is no better than placebo or clozapine. Based on new information, clinicians must 95 
re-evaluate traditional viewpoints on the use of quetiapine for psychosis in parkinsonism. 96 
 97 
Keywords: Parkinson Disease, parkinsonism, hallucinations, quetiapine, psychosis  98 
 99 
INTRODUCTION 100 
The most common neurodegenerative form of parkinsonism is Parkinson disease (PD) which is a 101 
clinical syndrome characterized by lesions in the basal ganglia, predominantly in the substantia 102 
nigra. Parkinson disease makes up approximately 80% of cases of parkinsonism and it is 103 
recognized that non-motor symptoms are prominent {1,2}.  Much current clinical research 104 
surrounds the frequency and impact of non-motor symptoms on patients with parkinsonism, 105 
including Parkinson disease psychosis (PDP) which is common but frequently underrecognized 106 
and undertreated {3}.  Psychotic symptoms will develop in up to 60% of patients with PD and in 107 
up to 75% of patients with PD and concurrent dementia {3,4}.  108 
The care of patients with PDP is associated with significant healthcare utilization. In a 109 
Medicare survey of claims data from 2000 to 2010, patients with PDP had higher all-cause costs 110 
and resource utilization {3}. The highest annual cost differentials were found in long-term care 111 
costs ($31,178 for PDP vs $14,461 for PD without psychosis), skilled nursing facility costs 112 
($6601 for PDP vs $2067 for PD without psychosis), and inpatient costs ($10,125 for PDP vs 113 
$6024 for PD without psychosis). Long-term care utilization and expenditures were also 114 
significantly higher for PDP patients, spending an average of approximately 179 days in long-115 
term care, compared with 83 days for patients with PD without psychosis.   116 
The presence of psychotic symptoms is not only an independent cost-driving factor, but 117 
also intrusive to the patient’s daily life and a significant determinant of increased caregiver 118 
burden, sometimes exceeding that imposed by the motor symptoms that are classically associated 119 
with PD {5,6}. In a community-based PD sample, minor symptoms of PDP (e.g., illusions, sense 120 
of presence, passage hallucinations) were associated with more depressive symptoms and worse 121 
quality of life {7}.  The presence of hallucinations and psychotic symptoms are also an 122 
independent risk factor for nursing home placement and mortality in PD patients {8,9}.  When 123 
patients with PDP are admitted to long-term care (LTC) facilities, their associated disruptive 124 
behaviors can have a significant effect on LTC personnel and other LTC residents.  125 
 Balancing control of the motor and psychiatric symptoms of parkinsonism has 126 
historically been challenging because of a paucity of evidence-based strategies. Quetiapine is 127 
indicated for the treatment of schizophrenia and bipolar disorder, however it is commonly used 128 
off-label for the management of psychosis in parkinsonism. For patients with this condition, 129 
quetiapine dosing is titrated from 12.5 mg nightly up to a range of 50 to 150 mg per day {10}. 130 
Quetiapine is similar in structure to clozapine and has antagonist activity at histamine, 131 
muscarinic, and serotonin 5-HT2A receptors, with minimal affinity for dopaminergic D2 receptor 132 
{11}. In the American Academy of Neurology evidence-based practice parameter on the 133 
treatment of psychosis in PD, quetiapine was classified as Level C (i.e., possibly effective) {12}. 134 
A task force of the International Parkinson and Movement Disorder Society concluded in an 135 
evidence-based report that because of conflicting data on the efficacy of quetiapine and study 136 
methodology concerns (e.g., small sample size, low-quality rating), there is insufficient evidence 137 
for quetiapine for the treatment of PDP {13}. A joint task force of the European Federation of 138 
Neurological Societies and the Movement Disorder Society – European Section recommends 139 
quetiapine as possibly useful {14}. Subsequent to the publication of these evidence-based 140 
statements, the use of quetiapine and other antipsychotics in patients with PD has been found to 141 
be associated with an increased risk of mortality (quetiapine hazard ratio of 2.16 [95% CI, 1.88-142 
2.48] over nonuse) {15} in a Veteran Administration PD population, and a new molecular entity, 143 
pimavanserin, was FDA approved for the treatment of PDP. Given these new developments, it is 144 
important to re-evaluate the role of quetiapine in the treatment of psychosis in patients with 145 
parkinsonism. 146 
 147 
METHODS 148 
Literature Search Strategy and Data Sources 149 
 The literature search strategy was designed to identify randomized controlled trials 150 
(RCTs) of quetiapine in the treatment of psychosis in patients with parkinsonism. The literature 151 
search was performed using these databases: PubMed, Cochrane Central Register of Controlled 152 
Trials, and EMBASE. The search used the keyword “quetiapine.’’  We limited our search to 153 
English language-only articles published from January 1991 to October 2017. Additionally, we 154 
manually searched the reference lists of identified publications for additional studies to 155 
supplement our electronic search. 156 
 157 
Study Selection 158 
Two reviewers (JC, LM) performed the literature research in parallel and independently. 159 
Reviewers discussed and selected articles to be included. Studies were included in the qualitative 160 
review if they: 1) were randomized and controlled with either placebo or an active comparator, 161 
2) enrolled subjects with a diagnosis of parkinsonism, 3) assessed the efficacy of quetiapine on 162 
psychotic symptoms, and 4) evaluated adverse effects including motor outcomes. When 163 
disagreement arose between screeners on studies to be included in the final synthesis, a third 164 
reviewer resolved the discrepancy. 165 
The first level of screening examined the title and abstract of publications for inclusion or 166 
exclusion. At the second level of screening, the full text of publications were retrieved and 167 
reviewed for inclusion or exclusion. Reference lists were also screened to identify additional 168 
studies. At the final level of screening, data were extracted from the final list of RCTs.    169 
 170 
Data Extraction and Quality Assessment 171 
Study methodology, patient, and treatment-level data were extracted from full text publications 172 
under predefined headings. Each study underwent quality assessment for risk of bias based on 173 
Cochrane metrics {16}. The quality assessment for RCTs systematically addressed seven types 174 
of bias: random sequence generation, allocation concealment, blinding of participants and 175 
personnel, blinding of outcome assessment, incomplete outcome data, selective outcome 176 
reporting, and other sources of bias.  177 
 178 
RESULTS 179 
Studies Identified 180 
The systematic literature search identified seven studies on the efficacy of quetiapine in 181 
treating psychosis in parkinsonism (including PD psychosis, dementia with Lewy bodies, 182 
dementia with parkinsonian features) (Figure 1). Five of the RCTs compared quetiapine to 183 
placebo {17-22}, and two RCTs compared quetiapine to clozapine {23,24}. A summary of the 184 
RCT results is provided in Table 1. The seven unique RCTs included a total of 241 subjects with 185 
parkinsonism and psychosis. Quetiapine at doses between 12.5 mg and 300 mg per day (mean 186 
daily dose of 103 mg) administered from four to 22 weeks (mean duration of 12 weeks) failed to 187 
significantly reduce psychotic symptoms in subjects with parkinsonism compared to placebo or 188 
clozapine when objectively assessed on the BPRS, the most frequently reported scale in these 189 
RCTs. In the two clozapine-comparator controlled studies, quetiapine demonstrated no 190 
advantage over clozapine in terms of efficacy or adverse effects and in one of the studies {23}, 191 
hallucination and delusion scores favored clozapine over quetiapine. Overall, the mean 192 
completion rates for all groups were poor and rates did not differ between quetiapine and 193 
placebo-treated subjects. Across all RCTs, the completion rates for quetiapine, clozapine, and 194 
placebo were 66%, 68.5%, and 66%, respectively. Among the two RCTs comparing the efficacy 195 
of quetiapine to clozapine, the completion rates were more favorable compared to clozapine, 196 
(80% and 68.5%, respectively) {23,24}.  197 
Overall, adverse effects reported in quetiapine-treated subjects include, confusion, 198 
dizziness, headache, orthostatic hypotension, somnolence, and worsening parkinsonism. 199 
Although individual RCTs reported quetiapine-associated worsening of parkinsonism, the overall 200 
data demonstrates quetiapine does not significantly worsen motor function as measured by 201 
UPDRS motor scores. The systematic quality assessment revealed that all RCTs were subject to 202 
high risk of attrition bias due to incomplete outcome data (Table 2). 203 
 204 
Details of Studies 205 
Fernandez et al. performed a randomized, double-blind, placebo-controlled study on the 206 
use of quetiapine for subjects with PD and visual hallucinations {17}. Subjects were randomly 207 
assigned to treatment arms and initiated at 25 mg of quetiapine or matching placebo at bedtime. 208 
Dosage increased by 25 mg increments every 3 to 7 days until reaching a maximum dosage of 209 
150 mg, or the complete cessation of nocturnal hallucinations. The primary dependent variable 210 
was the length of REM sleep, measured by polysomnography. The quetiapine group increased in 211 
the length of their REM sleep (mean increase = 13.6 min), and the placebo group decreased in 212 
REM sleep (mean decrease = 28.3 min), but the difference between groups was not statistically 213 
significant. Hallucination severity was self-reported in one item of the Brief Psychiatric Rating 214 
Scale (BPRS), which presents a series of psychiatric symptoms rated on a 7-point scale in which 215 
larger scores indicated greater severity. Although the quetiapine group experienced greater 216 
reduction in hallucination severity (mean reduction 1.32, SD = 1.13) than the placebo group 217 
(mean reduction 0.04, SD = 0.82), P=0.02, the change in total BPRS scores was not statistically 218 
different between groups. There were no statistically-significant differences between quetiapine 219 
and placebo in Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores or in the 220 
number of adverse events experienced by either group. The completion rate was only 68.75% (11 221 
out of 16 subjects), with 50% of the quetiapine group and 87.5% of the placebo group finishing 222 
the study. Notable reasons for termination from the quetiapine group were lack of efficacy in 223 
treating hallucinations (experienced by two subjects), and one subject who dropped out because 224 
of an adverse event, drowsiness. 225 
A randomized, double-blind, placebo-controlled, parallel group study by Kurlan et al. 226 
assessed the effect of quetiapine on agitation and psychosis on subjects with dementia, PD, or 227 
Alzheimer’s disease with PD features {18}. Quetiapine and placebo groups started treatment at a 228 
dosage of 25 mg of quetiapine or placebo. Dosage was increased, as necessary, up to an 229 
additional 25 mg every 2 days and up to an absolute limit of 150 mg twice daily. Quetiapine 230 
efficacy was assessed using the BPRS, and motor function was assessed using the motor 231 
subscale of the UPDRS. Statistical analysis failed to find any statistically significant difference 232 
between quetiapine and placebo groups on efficacy, adverse events, or change in UPDRS. The 233 
study-wide completion rate was 75% (30 out of 40 subjects). The quetiapine group had 85% 234 
completion, and the placebo group had 65% completion. The authors reported that the most 235 
common reasons for dropout were concern over placebo (one in each treatment group), 236 
effectiveness of medication (two in the placebo arm, one in the quetiapine arm), and adverse 237 
effects (three in the placebo arm, one in the quetiapine arm).  238 
Ondo et al. conducted a double-blind, placebo-controlled, 2:1 randomized, parallel trial to 239 
evaluate the efficacy of quetiapine in treating hallucinations in subjects with PD {19}.  The first 240 
three weeks of treatment were two doses of quetiapine per day—one in the afternoon, one at 241 
night—titrating up to 50 mg per dose. Weeks 4-6 of treatment maintained two doses per day 242 
while titrating up to a maximum of 200 mg per dose. Hallucinations were assessed with the 243 
BPRS and the Baylor PD Hallucination Questionnaire. On the Baylor PD Hallucination 244 
Questionnaire, subjects in the quetiapine group had a non-significant trend toward improvement 245 
(P=0.20).  The quetiapine group and placebo had comparable outcomes regarding the change in 246 
total BPRS score and change in the score on the BPRS hallucination item. The main adverse 247 
events in the drug group were sedation (40%), and subjective worsening in PD (19%) although 248 
there was no statistically-significant worsening of parkinsonism on the UPDRS motor scores. 249 
Twenty-six out of 31 subjects (83.87%) completed the study, with 80.95% completion from the 250 
quetiapine group and 80% from the placebo group. Reasons for dropout from the quetiapine 251 
group included serious unrelated illness, lack of effectiveness, and noncompliance. The placebo 252 
group had two dropouts from unrelated serious illness. 253 
Rabey et al. performed a double-blind, placebo-controlled RCT on the efficacy of 254 
quetiapine on drug-induced psychosis in subjects with PD {20}. All the subjects in this study had 255 
been successfully treated with dopaminergic medication for at least 2 years prior to recruitment. 256 
Subjects had psychotic symptoms (hallucinations and/or delusions), which significantly affected 257 
the subject’s quality life. Subjects were randomly assigned to either the quetiapine or placebo 258 
group for 12 weeks of treatment. Both groups began with one 12.5 mg dose of quetiapine or 259 
placebo per day. Over a titration period of up to 4 weeks, dosage increased until the psychotic 260 
symptoms resolved or side effects became severe. The outcomes experienced by the quetiapine 261 
group and placebo group were comparable, and the differences were not statistically significant. 262 
There were no statistically significant differences in the UPDRS motor scores from baseline to 263 
final point of assessment in either group. The most commonly occurring adverse event was 264 
somnolence, seen in seven subjects from the quetiapine group and two subjects from the placebo 265 
group. The study-wide completion rate was 55.17% (32 of 58 subjects), with 50.00% completion 266 
in the quetiapine group and 60.71% completion in the placebo group. The most common reason 267 
for dropout was a lack of therapeutic response, which occurred in 10 of 15 dropouts in the 268 
quetiapine group and 9 of 11 dropouts in the placebo group. Three subjects in the quetiapine 269 
group discontinued treatment due to side effects, of which two were due to somnolence. 270 
Shotbolt et al. conducted a double-blind placebo-controlled RCT to evaluate the efficacy 271 
of quetiapine for psychosis in PD {21,22}. The study period lasted 12 weeks, during which 272 
subjects were started on a daily dose of 25 mg of quetiapine or placebo and titrated through the 273 
first 6 weeks up to a maximum dosage of 50 mg in the morning and 100 mg at night. The 274 
primary dependent variable was the time remaining in treatment at the time of dropout. This 275 
outcome was based on the theory that “patients would drop out if their psychosis failed to 276 
improve or deteriorated and would stay in if their symptoms were improving.” On average, 277 
subjects in the quetiapine group dropped out sooner than those in the placebo group, but this 278 
difference was not statistically significant. The secondary assessment measures were the UPDRS 279 
total score, UPDRS Motor score, BPRS, Neuropsychiatric Inventory (NPI), and Baylor PD 280 
hallucination scale; none of these measures showed statistically significant changes between 281 
baseline and final observation. The quetiapine group had three adverse events—all drowsiness—282 
followed by dropout, and the placebo group also had three adverse events—two cases of 283 
drowsiness, one case of confusion—followed by dropout. 284 
Clozapine has improved psychosis in PD in two multicenter, placebo-controlled trials and 285 
is commonly used in clinical practice {25,26}. We identified two RCTs that compared 286 
quetiapine to clozapine and met inclusion criteria {23,24}. Merims et al. randomly assigned 287 
subjects with psychosis and PD to receive treatment with quetiapine or clozapine and assessed 288 
outcomes with the delusion and hallucination items of the NPI and the Clinician Global 289 
Improvement-Change Scale (CGI-C) {23}. Although the hallucination frequency was reduced 290 
for both the treatment groups, the baseline-to-final-assessment difference was statistically 291 
significant for only the clozapine group. Subjects in the clozapine group experienced a 292 
statistically-significant reduction in the frequency of delusions whereas subjects assigned to 293 
quetiapine actually increased delusion frequency, but not to a consistent degree. The change in 294 
CGI-C scores were comparable between the two treatment arms. The article lists UPDRS total 295 
score but not the motor score; however, the authors state, “We did not observe any worsening in 296 
parkinsonian symptoms as measured by the UPDRS […] in any of the treatment arms.” Only 297 
59.26% of the subjects (16 out of 27) completed the study: 69.23% of the quetiapine group and 298 
50.00% of the clozapine group. Lack of treatment efficacy was the most common cause for 299 
dropout from the quetiapine group, and a decreased leukocyte count was the most common cause 300 
for dropout from the clozapine group.  301 
In the second RCT that compared quetiapine to clozapine, Morgante et al. randomly 302 
assigned subjects with psychosis in PD to either quetiapine or clozapine treatment to assess 303 
effect on hallucinations, suspiciousness, and hostility {24}. Outcome measurements included the 304 
BPRS, Clinician Global Improvement-Severity Scale (CGI-S), Abnormal Involuntary Movement 305 
Scale (AIMS), and the total score of the UPDRS. Although the outcome assessors were blinded 306 
to the treatment assignments, the subjects were informed about the drug they were receiving. The 307 
starting dose was 25 mg per day of quetiapine or 6.25 mg per day of clozapine. Dosage was 308 
titrated by a neurologist aware of the treatment conditions, with maximum doses of 200 mg daily 309 
of quetiapine or 50 mg daily of clozapine. Post-treatment scores on the BPRS, CGI-S, and AIMS 310 
were improved compared to baseline for both the quetiapine and the clozapine groups. Overall, 311 
the UPDRS scores remained unchanged, however a mild worsening of parkinsonism was 312 
observed in three patients treated with quetiapine (greater than 100 mg per day). The efficacy of 313 
both drugs was comparable, as the differences between quetiapine and clozapine groups were not 314 
statistically significant. Both groups experienced a small number of adverse events, but no 315 
inferential statistics were provided comparing quetiapine to clozapine. The majority of the 316 
subjects, 88.89% (40 out of 45) completed the 12-week study: 90.91% of the quetiapine group, 317 
86.96% of the clozapine group. One subject in the quetiapine group withdrew because of 318 
sedation, and another subject withdrew due to a “confusional state.” Dropout in the clozapine 319 
group was attributed to sedation, dizziness, and severe hypotension. 320 
 321 
DISCUSSION 322 
The aim of this comprehensive systematic literature review is to qualitatively evaluate the 323 
efficacy and safety (including effects on motor function) of quetiapine as compared to placebo or 324 
other interventions for the treatment of psychosis in parkinsonism. Our methodology aimed to 325 
gather data for all forms of parkinsonism and we found that the published RCT evidence is 326 
dominated by investigations of patients with psychosis and idiopathic PD. 327 
 In a network meta-analysis, Iketani et al. report that the utility of quetiapine for the 328 
treatment of psychosis (assessed by BPRS) in patients with idiopathic PD is inferior to that of 329 
placebo and that use of quetiapine was likely to lead to deterioration of motor function {27}. The 330 
meta-analysis by Iketani et al was confined to RCTs of subjects with idiopathic PD. 331 
Additionally, the meta-analysis included only four unique (i.e., non-redundant reports) RCTs of 332 
quetiapine which comprised a total of 138 subjects. In our current study, we analyzed data from 333 
seven unique studies with a total of 241 subjects with parkinsonism and psychosis (including PD 334 
psychosis, dementia with Lewy bodies, dementia with parkinsonian features) who were 335 
randomized to receive either quetiapine or a comparator (placebo or clozapine). Quetiapine at 336 
doses between 12.5 mg and 300 mg per day (mean daily dose of 103 mg) administered from four 337 
to 22 weeks (mean duration of 12 weeks) failed to significantly reduce psychotic symptoms in 338 
subjects with parkinsonism compared to placebo or clozapine when objectively assessed on the 339 
BPRS, the most frequently reported scale in these RCTs. Overall, in four of five placebo-340 
controlled RCTs, quetiapine failed to significantly improve psychosis. In two clozapine-341 
comparator controlled studies, quetiapine demonstrated no advantage over clozapine in terms of 342 
efficacy or adverse effects and in one of the studies, hallucination and delusion scores favored 343 
clozapine over quetiapine.  344 
 Across all RCTs, mean completion rates for all groups were similarly poor. The RCT 345 
completion rates for quetiapine and placebo were no different and this suggests that dropouts 346 
cannot be substantively attributed to quetiapine dose titration methodologies. However, 347 
completion rates for quetiapine were more favorable compared to clozapine. Overall, adverse 348 
effects reported in quetiapine-treated subjects include, confusion, dizziness, headache, orthostatic 349 
hypotension, somnolence, and worsening parkinsonism. Despite reports of worsening 350 
parkinsonism, the overall data demonstrates quetiapine does not significantly worsen motor 351 
function as measured by UPDRS motor scores. The regularity of discontinuations due to adverse 352 
effects associated with quetiapine in subjects with psychosis and parkinsonism indicates that use 353 
of quetiapine in this population may not be as well tolerated as traditionally believed. The most 354 
common adverse effects leading to quetiapine discontinuation were confusion and somnolence. 355 
 In 2008, a task force of the International Parkinson and Movement Disorder Society 356 
published a critique of rating scales for the assessment of psychosis in PD and recommended 357 
four scales for use in clinical studies: the Brief Psychiatric Rating Scale (BPRS), 358 
Neuropsychiatric Inventory (NPI), Positive and Negative Syndrome Scale (PANSS), and the 359 
Scale for Assessment of Positive Symptoms (SAPS) {28}. The task force labeled these scales as 360 
“recommended” with the caveat that none contained all the basic content, mechanistic and 361 
psychometric properties to be deemed adequate for capturing the entire phenomenology of PD 362 
psychosis and that none have undergone formal psychometric evaluation in patients with 363 
psychosis and PD. Given the limitations of the recommended scales, the task force also 364 
recommended using the Clinician Global Improvement-Change Scale (CGI-C) as a secondary 365 
outcome scale to complement the more detailed psychosis rating scales. We found that of the 366 
seven RCTs in our study, six utilized the BPRS as a primary outcome and all utilized the CGI-C 367 
as a secondary outcome. This is consistent with the task force recommendations and 368 
representative, at that time, of best practice for clinical research in psychosis with PD. Despite 369 
this, the RCTs failed to reveal any statistically significant differences between quetiapine and 370 
placebo or clozapine for efficacy. 371 
 The failure to detect a statistically significant difference could also have been due to 372 
underpowering of the RCTs and the overall poor completion rates for treated and placebo 373 
groups in some studies. Additionally, none of the psychosis rating scales utilized in the 374 
quetiapine RCTs (i.e., Baylor PD Hallucination Questionnaire, BPRS, NPI) have undergone 375 
psychometric evaluation in the parkinsonism population {28} and it is possible that the lack 376 
of detecting significant differences between quetiapine and placebo or clozapine may be due 377 
to issues of instrument reliability, validity, and/or sensitivity. Given the psychometric 378 
limitations of the rating scales utilized in the seven RCTs, we believe that performing a 379 
quantitative analysis (i.e., meta-analysis) would only have yielded quantitatively 380 
indeterminant results and would not substantively alter any clinically relevant conclusions 381 
reached by our qualitative study.     382 
 Quetiapine has traditionally been widely prescribed for the treatment of psychosis in 383 
patients with PD due to clinical impressions of efficacy and tolerability. Use of quetiapine, 384 
unlike clozapine, does not requires mandated laboratory monitoring and, unlike other 385 
antipsychotics, is not generally associated with worsen of motor function. Generally, quetiapine 386 
is considered to be well tolerated. We found that the RCT completion rate of quetiapine-treated 387 
subjects was no better than placebo. However, rates were better than that for clozapine-treated 388 
subjects. Additionally, the psychosis rating scales utilized to measure efficacy outcomes in the 389 
quetiapine RCTs have not been deemed psychometrically suitable for this utility. Given our 390 
negative findings and the emerging data of increased mortality in PD patients treated with 391 
quetiapine and other antipsychotics as well as the recent introduction of a novel antipsychotic 392 
pimavanserin for treatment of psychosis in PD, the overall treatment landscape for psychosis in 393 
parkinsonism has evolved to a point in which clinicians must recalibrate the traditional clinical 394 
impression of quetiapine efficacy and tolerability for psychosis in parkinsonism. 395 
   396 
CONCLUSION 397 
Quetiapine has not demonstrated better efficacy compared to placebo or clozapine for treatment 398 
of psychosis in parkinsonism. Overall, quetiapine is not associated with significant worsening of 399 
motor function. However, the RCT completion rates of quetiapine-treated subjects are no better 400 
than placebo with treatment-emergent somnolence the most common reason for study 401 
discontinuation.  402 
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